AFT Pharmaceuticals Update

Market release
April 30 2018
AFT Pharmaceuticals concludes divestment of non-core products and is to announce full
year results on Wednesday May 23 2018

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) is pleased to confirm that it has concluded
agreement for AFT to divest to Baxter a range of their non-core hospital products currently
sold in Australia effective 1 June 2018. This follows on from the 21 March 2018
announcement that a similar agreement had been reached for New Zealand.

Hartley Atkinson, CEO of AFT, says that we are pleased to conclude the agreement for both
countries which fits in with AFT’s strategy of focusing on higher margin over-the-counter
products.

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) also announces that it intends to release on
Wednesday May 23 2018 its financial results for the year ended March 31 2018. The release
will be issued at around 09:00.

This will be followed by a presentation by management at 10:00 by teleconference. The
presentation material which will be referred to by management will be issued at around 09:00
and will also be available on the company’s website aftpharm.com.

To attend the conference call please dial in on one of the numbers below at least five minutes
before the scheduled call time, identify yourself to the operator and provide the following
confirmation code: 9335 578

Confirmation code: 9335 578

Phone numbers:

Australia 02 8038 5221 New Zealand 09 8876 907
1800 123 296 0800 452 782



[End of release]

Contact:
Malcolm Tubby
Chief Financial Officer
AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232